olprinone has been researched along with endothelin-1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koide, H; Nakamura, T; Shimada, N; Suzuki, S; Ushiyama, C | 1 |
| Inagaki, M; Ishikawa, S; Mitsui, T; Onizuka, M; Sato, Y; Tomoyasu, M; Yamamoto, T | 1 |
1 trial(s) available for olprinone and endothelin-1
| Article | Year |
|---|---|
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Topics: Adult; Cardiotonic Agents; Endothelin-1; Female; Heart Failure; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Pyridones; Tumor Necrosis Factor-alpha | 2002 |
1 other study(ies) available for olprinone and endothelin-1
| Article | Year |
|---|---|
Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiac Output; Central Venous Pressure; Cyclic Nucleotide Phosphodiesterases, Type 3; Disease Models, Animal; Endothelin-1; Enzyme Inhibitors; Female; Heart Failure; Imidazoles; Lung; Male; Models, Cardiovascular; Pyridones; Renal Circulation; Sheep; Shock, Cardiogenic; Thoracic Duct; Time Factors; Treatment Outcome; Vascular Resistance | 2002 |